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The prognosis of locally advanced esophageal cancer patients
is poor. Trimodality therapy of surgical resection plus neo-
adjuvant chemoradiotherapy (nCRT) has been developed to
improve survival outcomes of locally advanced esophageal
cancer. Combination therapy appears to be more effective
than either chemotherapy or radiotherapy alone because
chemotherapeutic agents can act as radiosensitizers to
improve locoregional control and prevent micrometastasis.
Some previous reports have shown a survival benefit with the
use of nCRT compared with surgery alone.1e3
Currently, the standard nCRT is fluorouracil (5-FU) and
cisplatin in Japan. However, we administered oral fluo-
ropyrimidine (S-1) and low-dose cisplatin for clinical Stage
II/III esophageal cancer at our institution. S-1 has been
approved in Japan for many malignancies, but limited data
are available for esophageal cancer.4 Recently, combina-
tion chemotherapy with S-1 and cisplatin has been widely
studied in advanced gastric cancer.5e7
In 2008, an American Society of Clinical Oncology ab-
stract showed that S-1 plus cisplatin was superior to
continuous infusion of 5-FU plus cisplatin. Outside Asia,
despite differences in S-1 dose and schedule from Asian
trials, S-1 plus cisplatin was associated with fewer toxic
effects, slightly improved survival, and equal efficacy when
compared with 5-FU plus cisplatin.8 Further, S-1 combined
with low-dose cisplatin has been reported to be effective,
with tolerable toxicity.6
We hypothesized that the effect of surgery plus nCRT
with S-1 and low-dose cisplatin will be effective with low
toxic effects in patients with esophageal cancer as well as
gastric cancer. Therefore, the aim of this study was to
clarify the efficacy and safety of nCRT plus esophagectomy
for clinical Stage II/III esophageal cancer.
2. Materials and methods
2.1. Patients
All patients provided written informed consent. The study
was approved by the Institutional Review Board to ensure
the protection of patient privacy and confidentiality. The
study was undertaken in accordance with the ethical
standards of the World Medical Association Declaration of
Helsinki.
This retrospective cohort study included 28 Japanese
patients (5 females and 23 males; median age, 69.8  8.3
years) who underwent nCRT plus esophagectomy forkahashi K, et al., Study of neoadju
sophageal cancer, Asian Journalpreoperative clinical Stage II/III esophageal cancer between
January 2008 and April 2015 at our institution. All patients
were staged preoperatively and postoperatively according to
the tumorenodeemetastasis classification of the American
Joint Committee on Cancer Staging Version 7.9 Prior to
administering nCRT, all patients were staged by endoscopic
ultrasound (EUS) and biopsy, computed tomography (CT), or
positron emission tomography (PET). All pathological speci-
mens from the initial endoscopic biopsies were read and
confirmed by pathologists specializing in gastrointestinal
malignancies. The eligibility criteria for this study were
as follows: age < 85 years, adequate organ function (white
blood cell count  3500, hemoglobin  10 g/dL, aspartate
aminotransferase/alanine aminotransferase 2  the upper
limit of normal, platelet count 100,000/mm3, serum
creatinine  2.0 mg/dL), and a performance status of <2 at
the time of admission. Exclusion criteria included the
following: Patients with distant metastases and any previous
palliative therapy or incomplete healing from previous major
oncological surgery.
The patients received S-1 and low-dose cisplatin and
nCRT concurrently, plus surgery. The medical data
collected included those on patient characteristics, post-
treatment characteristics, surgical outcome, clinicopatho-
logical findings, prognosis, and toxicity. Follow-up data
were obtained from the patients’ medical records and their
referring physicians.
Postoperative complications were defined as complica-
tions occurring by postoperative Day 90. Postoperative
mortality was defined as death occurring during hospitali-
zation for the operation.
Toxicity was graded on the basis of the National Cancer
Institute Common Terminology Criteria (NCI-CTC)
guidelines.
Following nCRT and esophagectomy, postoperative
pathological staging was compared to the initial staging to
assess the effect of nCRT and subsequent downstaging or
upstaging.
Pathological examinations included tumor detection and
the assessment of invasion depth, metastatic lymph node
number, and surgical margins. Tumor regression grades
were defined by the Japan Esophageal Society as follows:
Grade 3, markedly effective, with no viable cancer cells
[pathological complete response (pCR)]; Grade 2, moder-
ately effective, with viable cancer cells accounting for less
than one-third of the tumor tissue (partial response); Grade
1, slightly effective, with viable cancer cells accounting for
one-third or greater of the tumor tissue (low efficacy);
Grade 0, ineffective, with no recognizable cytological or
histological therapeutic effect (poor efficacy). Downstagingvant chemoradiotherapy with combined S-1 and low-dose cisplatin
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pathological staging (ypTNM) compared with the clinical
staging (cTNM).10,11
We examined the clinical efficacy and safety of nCRT
plus esophagectomy for clinical Stage II/III esophageal
cancer. The primary endpoints were overall survival (OS)
and disease-free survival (DFS). The secondary endpoints
were overall response rates (RR) and safety.
2.2. Chemotherapy regimen
All patients gave written informed consent before enroll-
ment. Patients with no evidence of metastatic disease and
good performance status were referred for surgical resec-
tion. All patients preoperatively received a regimen of S-1
plus low-dose cisplatin. One course of treatment consisted
of 5-week cycles. Oral S-1 (80 mg/m2 in two doses) was
given daily for the first 3 weeks, followed by 2 weeks of rest.
Low-dose cisplatin (10 mg) was given as a 6-hour infusion on
Days 1e5 and Days 8e12 (10 days, total 100 mg). One
chemotherapy cycle was administered before surgery.
2.3. Radiotherapy planning
All patients were treated with helical tomotherapy (Accu-
ray, Tokyo, Japan), which is a novel treatment approach
where the ring gantry irradiation geometry of a helical CT
scanner is combined with an intensity-modulated mega-
voltage X-ray (6 mV) fan beam. An inverse treatment
planning system was used to optimize the treatment plans.
Radiotherapy treatment technique was administered at the
discretion of the radiation oncologist; CT-based planning
was performed with the patients lying supine with arms up
on a Vac-Lock (Civco Medical Solutions, Kalona, IA, USA)
immobilization device. Four-dimensional CT simulation
scans were obtained to assess tumor motion during respi-
ration. A clinical target volume (CTV) encompassing a
4e5 cm superior margin, 3e4 cm distal margin, and
2.5e3 mm radial margin was contoured. For upper thoracic
tumors, bilateral supraclavicular lymphatics were included.
For distal esophageal and gastroesophageal cancers, celiac
nodes and nodes along the left gastric artery were always
included in the CTV. For gastroesophageal junction carci-
nomas, other regional abdominal nodal groups were
included on the basis of the magnetic resonance and/or
PETeCT imaging findings. The prescribed dose was either
20 or 30 Gy (2 Gy/fraction) depending on the tumor size
immediately before radiotherapy.
2.4. Surgical technique
Surgery was planned for 3e4 weeks following the
completion of nCRT. All patients underwent restaging with
EUS, CT, or PET 2e3 weeks following nCRT. Patients who
did not show evidence of metastatic disease and who were
deemed medically operable underwent esophagectomy.
All patients underwent at least two field lymph node
dissections and esophageal cancer in the upper and mid-
dle third of thoracic esophagus or lymph node metastasis
in the superior mediastinum was essentially treated
by cervical lymphadenectomy. Subsequently, the gastricPlease cite this article in press as: Takahashi K, et al., Study of neoadju
for patients with clinical stage II/III esophageal cancer, Asian Journal otube was lifted via the posterior mediastinal route and
cervical anastomosis of esophagus to gastric tube was
accomplished.
2.5. Follow-up method
We confirmed that this dose schedule was tolerable in all
patients. All patients were assessed every 3 months for the
first 5 years after the completion of treatment. Routine
follow-up exams included physical examination, history,
and CT of the chest/abdomen. Endoscopy was performed if
clinically indicated. CT of the chest/abdomen was per-
formed routinely every 6 months.
2.6. Statistical analysis
Statistical analysis was performed using JMP 11 (SAS Insti-
tute Inc., Cary, NC, USA). The results were expressed as the
mean  standard deviation and percentage. Grouped data
were expressed as the median (range) and nonparametric
methods were used. Patients were followed up periodically
until the last follow-up or death. OS was defined as the time
from the date of the initial treatment to patient death. DFS
was defined as the length of time after treatment during
which no cancer was found. Differences between the cu-
mulative survival rates of the tumor regression grades were
calculated by the log-rank test for comparison using
KaplaneMeier survival curves. A p value of < 0.05 was
considered statistically significant.
3. Results
3.1. Patient characteristics
All patients completed the nCRT regimen and underwent
esophageal resection. No treatment-related deaths were
observed. The median age was 69.8  8.3 years. All pa-
tients had squamous cell carcinoma. The clinical stages of
our patients before nCRT were Stage II in 10 patients
(35.7%) and Stage III in 18 patients (64.4%). On examining
the primary tumor location, upper thoracic tumors were
found in 5 patients (17.8%), middle and lower thoracic tu-
mors were found in 12 patients (42.9%), and 11 patients
(39.3%), respectively. Four patients (14.3%) had T0/T1 le-
sions and 24 patients (85.7%) had T2/T3 lesions. Twenty
patients had lymph node metastasis on CT at the time of
diagnosis. The patients received two field lymph node dis-
sections (46.4%) or three field lymph node dissections
(53.6%). All procedures were performed following the
guidelines provided by the Japan Esophageal Society. The
mean operating time was 333.2  23.9 min, and the mean
intraoperative blood loss volume was 690.0  6.7 mL. Other
characteristics of the patients in this study are summarized
in Table 1.
3.2. Perioperative complications
Perioperative complications were obtained through a
standardized review of the surgery database at our insti-
tution. The severity of each postoperative complicationvant chemoradiotherapy with combined S-1 and low-dose cisplatin
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Table 1 Patients characteristics.
Variables nZ 28
Gender (n, %)
Male 23 (82.1)
Female 5 (17.9)
Age (years, mean  SD) 69.8  8.3
PS (n, %)
0 18 (64.4)
1 10 (35.7)
BMI (kg/m2, mean  SD) 23.9  3.2
Tumor location (n, %)
Upper/middle/lower 5 (17.8)/12 (42.9)/11
(39.3)
Histology (n, %)
Squamous/adenocarcinoma 28/0
cT stage (n, %)
0 1 (3.5)
1 3 (10.7)
2 11 (39.3)
3 13 (46.4)
cN stage (n, %)
0 8 (28.6)
1 12 (42.9)
2 5 (17.8)
3 3 (10.7)
Extent of lymphadenectomy (n, %)
Two-field lymph node
dissections
13 (46.4)
Three-field lymph node
dissections
15 (53.6)
Operative time (minutes,
mean  SD)
333.2  23.9
Intraoperative blood loss (ml,
mean  SD)
690.0  6.7
Hospital stay
(days, mean  SD)
31.0  9.5
cStage (n, %)
II 10 (35.7)
III 18 (64.4)
Table 2 Postoperative mortality and morbidity.
Postoperative mortality
and morbidity
Patients
n (%)
Grade 3
n (%)
Hospital mortality 0
Reoperation 1 (3.5)
Overall morbidity 10 (35.7)
Surgical site infection 1 (3.5) 0
Anastomotic leakage 3 (10.7) 3 (10.7)
Chylothorax 2 (7.1) 2 (7.1)
Transient recurrent nerve palsy 0 0
Pulmonary complication 4 (14.3) 2 (7.1)
Arrhythmia 0 0
Table 3 Toxic effects of nCRT.
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
Hematologic toxicity
Leukopenia 10 (35.7) 5 (17.9) 4 (14.3) 0
Anemia 10 (35.7) 4 (14.3) 0 0
Thrombocytopenia 4 (14.3) 2 (7.1) 3 (10.7) 0
Renal dysfunction 1 (3.5) 0 0 0
Liver dysfunction 0 0 0 0
Non-hematologic toxicity
Fever 1 (3.5) 0 0 0
Fatigue 1 (3.5) 0 0 0
Nausea 1 (3.5) 0 0 0
Esophagitis 0 0 0 0
Mucositis 0 0 0 0
Diarrhea 0 0 0 0
4 K. Takahashi et al.
+ MODELwas evaluated using the ClavieneDindo classification.12
Grade 0, no complications; Grade I, deviation from the
normal postoperative course without the need for therapy;
Grade II, complications requiring pharmacological treat-
ments such as antibiotic administration; Grade III, compli-
cations requiring endoscopic, radiological, or surgical
intervention; Grade IV, life-threatening complications
requiring intensive care; Grade V, death. In the present
study, the postoperative hospital mortality rate was 0%.
Postoperative complications were observed in 10 patients
(35.7%) and 25% of patients had Grade III complications.
Anastomosis leakage was detected in three patients in this
study. Pulmonary complications such as atelectasis, pneu-
monia, and pulmonary insufficiency were observed in four
patients and chylothorax was observed in two patients. One
patient underwent reoperation for chylothorax. No patients
with Grade V complications were observed in this study.
The patients’ postoperative complications are summarized
in Table 2.Please cite this article in press as: Takahashi K, et al., Study of neoadju
for patients with clinical stage II/III esophageal cancer, Asian Journal3.3. Safety evaluation
In general, the patients tolerated nCRT well, and all pa-
tients completed treatment. No patients required dose
reduction, and there were no nCRT-related deaths. The
toxic effects of nCRT were evaluated using NCI-CTC. He-
matological toxic effects included leukopenia, neu-
tropenia, anemia, thrombocytopenia, renal dysfunction,
and liver dysfunction. Nonhematological toxic effects
included fever, fatigue, nausea, esophagitis, mucositis, and
diarrhea. Twenty-five percent of the patients had  Grade
3 toxicity, including leukopenia and thrombocytopenia.
Leukopenia was the most common type of toxicity associ-
ated with nCRT (Grade 3; 14.3%) and nonhematological
toxicity was mild. Nonhematological toxicity of Grades 3
and 4 was not observed in any of the patients. Radiation-
related late toxicity was also not observed. Other toxic
effects of nCRT are summarized in Table 3.3.4. Clinical efficacy and survival
Complete resection (R0 resection) was successfully
accomplished in all patients. Postoperative pathological
staging determined that 22 patients (78.5%) were down-
staged following nCRT, whereas no patients were upstaged.vant chemoradiotherapy with combined S-1 and low-dose cisplatin
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patients (28.6%) who underwent surgical resection. The RR
to nCRT was 92.9%. The postoperative pathological stages
were ypStage 0 in 4 patients (14.3%), ypStage I in 7 patients
(25%), ypStage II in 14 patients (50%), and ypStage III in 3
patients (10.7%). The pathological tumor staging and effect
of nCRT are shown in Table 4.Table 4 Pathologic staging and effect of nCRT.
Patients n (%)
ypT
0 8 (28.6)
1 7 (25)
2 5 (17.8)
3 8 (28.6)
ypN
0 17 (60.7)
1 6 (21.5)
2 4 (14.3)
3 1 (3.5)
ypStage
0 4 (14.3)
I 7 (25)
II 14 (50)
III 3 (10.7)
Down-staging(þ) 22 (78.5)
Pathologic effect of
primary tumor
Grade 1 2 (7.1)
2 18 (64.3)
3 8 (28.6)
Figure 1 KaplaneMeier curves of overall survival of (A) all patient
disease-free survival of all patients and (D) clinical Stage II/III pat
Please cite this article in press as: Takahashi K, et al., Study of neoadju
for patients with clinical stage II/III esophageal cancer, Asian Journal oThe median follow-up of this cohort was 20 months
(range, 1e83 months). The 1-year, 3-year, and 5-year OS
rates were 84.4%, 67.0%, and 67.0%, respectively, for Stage
II/III. The 1-year and 3-year OS rates were both 100% for
Stage II, and the 1-year, 3-year, and 5-year OS rates were
71.8%, 57.4%, and 57.4%, respectively, for Stage III. The OS
for all patients is shown in Figure 1. The 1-year, 3-year, and
5-year DFS rates were all 72.2% for Stage II/III. The 1- and 3-
year DFS rates were both 100% for Stage II, and the 1-year,
3-year, and 5-year DFS rates were all 59.3% for Stage III. The
DFS for all patients is shown in Figure 1.4. Discussion
The aim of this study was to clarify the efficacy, prognosis,
and safety of nCRT with S-1 and low-dose cisplatin plus
esophagectomy for Stage II/III esophageal cancer. nCRT
with S-1 plus low-dose cisplatin showed good efficacy and
prognosis with acceptable toxicity. We administered nCRT
with only one cycle of neoadjuvant chemotherapy and low
doses of radiotherapy. Nevertheless, the efficacy and
prognosis were favorable, with lower toxicity than that
found in previous trials.13e15
In regard to efficacy, nCRT with only one cycle of
chemotherapy (S-1 plus low-dose cisplatin), with low doses
of radiotherapy (20 or 30 Gy) for clinical Stage II/III
esophageal cancer patients contributed to a high RR for the
primary tumor and metastatic lymph nodes. In this study,
the RR to nCRT was 92.9%, pCR to nCRT was seen in 28% of
patients in this study, which is similar to that seen in pre-
vious studies by Donahue et al (26%), Kesler et al (29.4%),
and Courrech Staal et al (25.8%).1,16,17
Patients need to complete the full course of nCRT to
achieve good efficacy and prognosis. In this study, all thes and (B) clinical Stage II/III patients (C) Kaplan-Meier curves of
ients.
vant chemoradiotherapy with combined S-1 and low-dose cisplatin
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reduction. There were also no nCRT-related deaths. The
incidence of hematological and nonhematological toxicity
was lower than those seen in previous trials using 5-FU and
cisplatin regimens.18,19 There are various reasons for the
low toxicity observed in nCRT with S-1 plus low-dose
cisplatin. First, this regimen used S-1. A previous study
showed that S-1 had a greater effect on radiosensitivity in
cancer treatment than 5-FU.20 The doses of radiotherapy
were 20 or 30 Gy in this study. However, the doses of
radiotherapy were 40 to 60 Gy in other trial.2 S-1 had a
greater effect on radiosensitivity and thus, lower doses of
radiotherapy could be used in the current study than in
previous studies. Consequently, radiation-related toxicity
was not observed in the present study because of the low
doses of radiotherapy administered.21
Second, S-1 decreases gastrointestinal toxicity. S-1 is an
oral dihydropyrimidine dehydrogenase (DPD) inhibitory
fluoropyrimidine that combines three pharmacological
agents: tegafur, a pro-drug of 5-FU; gimestat, which in-
hibits DPD activity; and potassium oxonate, which de-
creases gastrointestinal toxicity. S-1 can provide efficacious
therapeutic plasma 5-FU concentrations by inhibiting DPD
activity while decreasing gastrointestinal toxicity, which is
one of the dose-limiting toxicities of 5-FU. In the present
study, gastrointestinal toxicity  Grade 3 was not observed.
Recently, continuous 5-FU infusion has been replaced by
the use of S-1 to avoid some of its adverse effects, partic-
ularly in stomach cancer.22
Finally, low-dose cisplatin decreases renal dysfunction
compared with standard-dose cisplatin. Renal dysfunction
is one of the most serious complications of cisplatin. A
previous report showed that the advantages of low-dose
cisplatin were a decreased risk of renal dysfunction, no
need for hydration, and lower incidences of nausea.23
Compared with high-dose regimens of cisplatin, low-dose
cisplatin appears to be equally effective, with a lower
risk of toxicity.23
The optimal time interval between nCRT and surgery is
not well defined. Generally, for patients receiving nCRT, a
2- to 8-week interval between nCRT and surgery is widely
accepted because it allows patients to recover from the
toxicity of chemoradiotherapy.24,25 The effect of nCRT is
thereby maximized, and there is more tumor shrinkage and
higher rates of pCR.26,27 However, delaying surgery after
nCRT completion raises the theoretical fears of tumor
regrowth and dissection difficulties related to radiation-
induced fibrosis, which may worsen surgical outcomes. A
previous report showed that a longer interval between
nCRT and surgery for esophageal cancer does not result in a
better outcome.1,28 There are theoretical concerns that if
surgery is delayed, dissection could be more difficult
because of increased radiation fibrosis.29,30 In a previous
randomized trial evaluating therapeutic approach, surgery
was performed within 2e8 weeks after nCRT completion.25
Although it is traditionally recommended to perform
esophagectomy within 8 weeks after nCRT, we performed
this surgery within 3e4 weeks after nCRT.
This study had some limitations inherent to observa-
tional studies. Firstly, in this study, the nonresponse group
was very small, which may explain the high rate of partial
response and pCR.Please cite this article in press as: Takahashi K, et al., Study of neoadju
for patients with clinical stage II/III esophageal cancer, Asian JournalNext, this study was not a comparative review. We
performed nCRT with S-1 and low-dose cisplatin plus
esophagectomy for Stage II/III esophageal cancer. Hence,
no patients received surgery alone or nCRT with other
regimens.
Finally, this study was performed as a retrospective
review in a single center with a limited number of patients.
Moreover, only squamous cell carcinoma patients were
enrolled. However, it is encouraging that our results are
comparable with previously published data. In future,
multicenter randomized controlled studies are required to
determine the effect of neoadjuvant chemo-
radiotherapeutic regimens.
5. Conclusion
In conclusion, the aim of this study was to clarify the effi-
cacy and safety of nCRT plus esophagectomy for clinical
Stage II/III esophageal cancer. Although we administered
only one cycle of neoadjuvant chemotherapy with low
doses of radiotherapy, the efficacy and prognosis were
favorable, and low toxicity was observed. From our data,
we conclude that this regimen is promising as nCRT for
esophageal cancer.Acknowledgments
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